Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) remains an incurable malignancy originating from plasma cells. Despite significant advances in treatment, relapses remain inevitable, and novel therapies continue to be needed. Teclistamab-cqyv is a first-in-class, bispecific T-cell engager (BiTE) antibody for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Gwen, Scanlan, Ryan, Straining, Rachael, Carlson, Daniel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Prescriber's Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062534/
https://www.ncbi.nlm.nih.gov/pubmed/37009408
http://dx.doi.org/10.6004/jadpro.2023.14.2.7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062534/
https://www.ncbi.nlm.nih.gov/pubmed/37009408
http://dx.doi.org/10.6004/jadpro.2023.14.2.7

Ejemplares similares